IACH News Podcasts
Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.
December 23rd 2024- Dr. Omran Saifi- Outcomes of Patients with R/R B-Cell NHL and Limited (<5 sites) pre-CAR T Disease Bridged With or Without Radiotherapy
December 12th 2024- Dr. Guillermo Garcia-Manero – COMMAND update
December 12th 2024- Dr. Amer Zeidan- Menin Inhibitors
December 12th 2024- Dr. Bhagirathbhai Dholaria- EA4151 Study, Late Breaking Abstract
December 9th 2024- Prof. Vincent Rajkumar- The AQUILA trial
December 3rd 2024- Prof. Gili Kenet- Gene Therapy for Hemophilia
November 28th 2024- Dr. Annalisa Ruggeri- Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies
November 17th 2024- Dr. Sarah Elitzur- ATM germline pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies
November 11th 2024- Prof. Mohamed Kharfan-Dabaja- How I treat Blastic Plasmacytoid Dendritic Cell Neoplasm
October 30th 2024- Prof. Shai Izraeli- Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms
October 23rd 2024- Prof. Per Ljungman- Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients for Use in Clinical Trials
October 13th 2024- Prof. Carlo Visco- More is Not Always Better
October 6th 2024- Dr. Natalia Zing- The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T-and NK-cell lymphomas
September 30th 2024- Prof. Yves Chalandon- Nilotinib with or without Cytarabine for Philadelphia-positive Acute Lymphoblastic Leukemia
September 20th 2024- Prof. Qian Jiang- A Predictive Model for Therapy Failure in CML Patients Receiving Tyrosine Kinase Inhibitor Therapy
September 13th 2024- Prof. Martin Ellis- Differential Effects of Itacitinib, Fedratinib, and Ruxolitinib in Mouse Models of Hemophagocytic Lymphohistiocytosis
September 2nd 2024- Prof. Mark Litzow- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
August 26th 2024- Prof. Olaf Penack- How risky is a second allogeneic stem cell transplantation?
July 22nd 2024- Dr. Kai Rejeski- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
July 16th 2024- Prof. Madhav Dhodapkar- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
July 7th 2024- Dr. Anand Patel- Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
June 24th 2024- Dr. Tamar Tadmor- Supplement of Vitamin D for early-stage Chronic Lymphocytic Leukemia Patients is Associated with a Longer Time to first Treatment
June 17th 2024- Prof. Saad Usmani- Antigen Escape as a Shared Mechanism of Resistance to BCMA-Directed Therapies in Multiple Myeloma
June 11th 2024- Dr. Zachariah DeFilipp- Flares of Acute Graft-Versus-Host Disease: a Mount Sinai Acute GVHD International Consortium Analysis
June 3rd 2024- Prof Saad Usmani- CD8 Effector T Cells Enhance Teclistamab Response in BCMA-Exposed and -Naïve Multiple Myeloma
May 24th 2024- Dr. Ruth Namazzi- Hydroxyurea reduces infections in children with sickle cell anemia in Uganda
May 20th 2024- Dr. Lorenz Bastian- Developmental trajectories and cooperating genomic events define molecular subtypes of BCR:ABL1-positive ALL
May 14th 2024- Prof. Didier Blaise- Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis
May 7th 2024- Prof. Ibrahim Yakoub-Agha- Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
April 30th 2024- Dr. Fadi Haddad & Prof. Elias Jabbour- Phase 2 Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission
April 17th 2024- Prof. Nigel Russell- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
April 10th 2024- Dr. Ofir Wolach- Molecular MRD is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy
March 25th 2024- Prof. Olaf Penack- Prophylaxis and Management of Graft-Versus-Host Disease After Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation
March 20th 2024- Prof. Michael Schmitt – Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
March 11th 2024- Dr. Adi Zoref Lorenz – Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Sweden: Incidence, Clinical Characteristics, and Survival
March 6th 2024- Prof. Katy Rezvani – Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19+ B Cell Tumors: a Phase 1/2 Trial
Feb 26th 2024- Prof. Marion Subklewe- Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Feb 23rd 2024- Guido Ghilardi & Marco Ruella- T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy
Feb 14th 2024- Dr. Joshua Fein- Simple Score of Albumin and CRP Predicts High Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
Feb 5th 2024- Prof. Ali Bazarbachi- Sorafenib Plus Intensive Chemotherapy in Newly Diagnosed FLT3-ITD AML: A Randomized, Placebo-Controlled Study by the ALLG
Feb 2nd 2024- Dr. Paula Rodriguez-Otero- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization approval for idecabtagene vicleucel (Abecma; ide-cel) for use in adult patients with relapsed and refractory multiple myeloma who previously received at least 2 therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody
Jan 23rd 2024- Prof. Daniel Wolff- Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with CGVHD Disease (AGAVE-201)
Jan 8th 2024- David Valcarcel & Adrian Mosquera- Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
Dec 19th 2023- Prof. Florent Malard- Gut Microbiota Diversity Before Allogeneic Hematopoietic Stem Cell Transplantation as a Predictor of Mortality in Children
Dec 12th 2023- Prof. Arnold Ganser – How I Treat Refractory and Relapsed Acute Myeloid Leukemia
Dec 5th 2023- Prof. Wolfgang Bethge- Outcomes of Axicabtagene Ciloleucel in PMBCL Compare Favorably with those in DLBCL: a GLA/DRST Registry Study
Nov 28th 2023- Prof. Ibrahim Yakoub-Agha- Nonrelapse Mortality After CAR T-cell Therapy for Large B-cell Lymphoma: a LYSA Study from the DESCAR-T Registry
Nov 21st 2023- Prof. Moshe Mittelman- A Randomized Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial
Nov 14th 2023- Dr. Bipin Savani- Vitamin C and D Supplementation in Acute Myeloid Leukemia
Nov 6th 2023- Prof. Attilio Olivieri- Incidence, Clinical Presentation, Risk Factors, Outcomes, and Biomarkers in De Novo Late Acute GVHD
Oct 30th 2023- Prof. Robert Zeiser- Phase 2 Study of Natalizumab Plus Standard Corticosteroid Treatment for High-Risk Acute GVHD
Oct 23rd 2023- Prof. Didier Blaise- Real World Experience of CAR T Cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Oct 16th 2023- Dr. Enrique Ocio- Melflufen Plus Dexamethasone and Daratumumab or Bortezomib in Relapsed/Refractory MM
Oct 9th 2023- Dr. Philippe Armand- Five-year follow-up of KEYNOTE-087
Oct 2nd 2023- Dr. Paul Richardson- Mezigdomide plus Dexamethasone in Relapsed and Refractory Myeloma
Sept 25th 2023- Dr. Akshay Sharma- CRISPR- Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease
Sept 19th 2023- Prof. Ephraim Fuchs- Cytokine Release Syndrome in Haploidentical Stem Cell Transplant May Impact T-cell Recovery and Relapse
Sept 12th 2023- Prof. Christina Peters- Poverty and Relapse Risk in Children with ALL: A Children’s Oncology Group Study AALL03N1 Report
Sept 7th 2023- Prof. Alvaro Urbano- Fractionated Initial Infusion and Booster Dose of ARI0002h, a Humanised, BCMA-Directed CAR T-cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma (CARTBCMA-HCB-01): a Single-Arm, Multicentre, Academic Pilot Study
Sept 5th 2023- Prof. Uwe Platzbecker- Recent Approval of Luspatercept as First-Line Treatment of Anemia in Adults with Lower-Risk MDS who May Require Transfusions
Aug 28th 2023- Prof. Michael Jordan- HLH-like Toxicities Predict Poor Survival After the Use of Tisagenlecleucel in Children and Young Adults with B-ALL
Aug 21st 2023- Dr. Ashwin Kishtagari- His Take on the Recent Approval of Quizartinib by FDA in AML
Aug 16th 2023- Dr. Jayastu Senapati- Prognostic Impact of Splicing Factor Mutations in Patients with Newly Diagnosed AML
Aug 8th 2023- Dr. Tania Jain- Haploidentical Donor Hematopoietic Cell Transplantation for MDS/MPN Overlap Neoplasms: Results from a North American Collaboration
Aug 1st 2023- Dr. Samer Al Hadidi- Risk of Infections Associated with the use of Bispecific Antibodies in Multiple Myeloma
July 25th 2023- Dr. Olalekan Oluwole- His Take on the Overall Survival Update from the Randomized ZUMA-7 Trial
July 17th 2023- Dr. Jordan Gauthier- CD19 CAR T-Cell Therapy & Prophylactic Anakinra in Relapsed or Refractory Lymphoma: Phase 2 Trial Interim Results
July 7th 2023- Bu-Flu Versus Bu-Cy for AML Patients Undergoing Haplo: a Multi Center Randomized Phase III Trial by Ling Yiwen and Colleagues
May 9th 2023- Dr. Olalekan Oluwole – Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL
May 5th 2023- Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation
Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy
Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Prof. Florent Malard- The First microbiota therapy approved by the US FDA
Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure
Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma
Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Prof. Mohamed Kharfan Dabaja – Positive Results from Final Progression-Free Survival Analysis of zanubrutinib Compared to ibrutinib in CLL
Prof. He Huang – Non-viral, specifically targeted CAR-T cells, achieve high safety and efficacy in B-NHL
Prof. Mikkael Sekeres – Azacitidine plus venetoclax for myelodysplastic syndromes
Dr. Adi Nagler – Single cell sequencing to chronic lymphocytic leukemia
Prof. Meral Beksac – The recent developments in the field of bispecific T-cell engagers
Prof. Selim Corbacioglu – The importance of veno-occlusive disease prophylaxis
Prof. Paul Richardson – Melflufen for the treatement of relapsed-refractory myeloma
Prof. Mohamad Mohty – New treatments for refractrory acute GVHD
Dr. Eolia Brissot – Approval of maribvir for post-transplant cytomegalovirus infection
Prof. Sebastian Giebel – CAR T cells for adult ALL
Prof. Farhad Ravandi – MRD in AML
Prof. Iskra Pusic – Recent updated in Acute GVHD
Prof. Arnon Kater -State of the art therapy in CLL
Annalisa Ruggeri – Haplo versus matched unrelated transplant at the era of post-cyclophosphamide
?
Christopher Hourigan – How to distinguish to Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis?
Robert Zeiser – REACH3 trial results
Alex Lazaryan – Belumosudil’s FDA approval for cGVHD
Monzr Al Malki – The role of post cyclophosphamide, for GVHD prophylaxis, in the mismatched unrelated setting
JNaveen Pemmaraju – Novel Therapeutic Approaches in BPDCN
Jurgen Kuball – Gammadelta T cells
Anna Sureda – Therapy of lymphomas, what’s new at EHA 2021
Nitin Jain – Therapy of CLL, what’s new at EHA 2021
Gram Jackson – Recently released paper on Improving prognostic assignment in older adults with MM
Mehdi Hamadani – Recently released ZUMA-7 trial results
Saad Usmani – Take-home messages, from ASCO, and EHA 2021
Luciano J. Costa – The role of auto in myeloma based on the ASCO 21 data
Jesus G. Berdeja – Results of the CARTITUDE-1 study
Arnon Nagler – Allo-transplant for AML: what’s new at EHA 2021
Mohamad Mohty – Advances in Multiple Myeloma as reported at EHA 2021
Ruben Mesa – Therapy of MPNs: what’s new at EHA 2021?
Dr. Jordan Gauthier – Results from Phase 3 TRANSFORM Trial
Dr. Jim Omel – The patient / cancer research advocate viewpoint from ASCO 2021
Prof. Mohamad Mohty – Multiple myeloma take home messages from ASCO 2021